CO6321285A2 - Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria - Google Patents
Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitariaInfo
- Publication number
- CO6321285A2 CO6321285A2 CO10051730A CO10051730A CO6321285A2 CO 6321285 A2 CO6321285 A2 CO 6321285A2 CO 10051730 A CO10051730 A CO 10051730A CO 10051730 A CO10051730 A CO 10051730A CO 6321285 A2 CO6321285 A2 CO 6321285A2
- Authority
- CO
- Colombia
- Prior art keywords
- cis
- treatment
- multiple sclerosis
- mielitis
- dihidrotetrabenazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1.- Un compuesto para usar en el tratamiento de la esclerosis múltiple donde el compuesto es una 3, 11b-cis-dihidrotetrabenazina de fórmula (la): o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0721669.0A GB0721669D0 (en) | 2007-11-02 | 2007-11-02 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6321285A2 true CO6321285A2 (es) | 2011-09-20 |
Family
ID=38834835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10051730A CO6321285A2 (es) | 2007-11-02 | 2010-04-30 | Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria |
Country Status (18)
Country | Link |
---|---|
US (1) | US20110039877A1 (es) |
EP (1) | EP2207551A1 (es) |
JP (1) | JP2011502977A (es) |
KR (1) | KR20100074234A (es) |
CN (1) | CN101932323A (es) |
AU (1) | AU2008320603A1 (es) |
CA (1) | CA2702134A1 (es) |
CO (1) | CO6321285A2 (es) |
CR (1) | CR11473A (es) |
EC (1) | ECSP10010145A (es) |
GB (1) | GB0721669D0 (es) |
IL (1) | IL204990A0 (es) |
MX (1) | MX2010003980A (es) |
NI (1) | NI201000047A (es) |
NZ (1) | NZ584846A (es) |
RU (1) | RU2010116859A (es) |
WO (1) | WO2009056885A1 (es) |
ZA (1) | ZA201003037B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
EA201691512A1 (ru) | 2014-01-27 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 |
CN108473489B (zh) | 2015-10-30 | 2022-09-02 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
SG11201906883SA (en) | 2017-01-27 | 2019-08-27 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
AU2018335259A1 (en) | 2017-09-21 | 2020-04-09 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
CA3077149A1 (en) | 2017-10-10 | 2019-04-18 | Neurocrine Biosciences, Inc. | Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
KR20210044817A (ko) | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
US20070037800A1 (en) * | 2005-06-23 | 2007-02-15 | Envivo Pharmaceuticals, Inc. | Method of treating neurological disorders using clotrimazole and derivatives thereof |
GB0516168D0 (en) * | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
-
2007
- 2007-11-02 GB GBGB0721669.0A patent/GB0721669D0/en not_active Ceased
-
2008
- 2008-10-29 CA CA2702134A patent/CA2702134A1/en not_active Abandoned
- 2008-10-29 KR KR1020107009333A patent/KR20100074234A/ko not_active Application Discontinuation
- 2008-10-29 US US12/740,786 patent/US20110039877A1/en not_active Abandoned
- 2008-10-29 CN CN2008801137150A patent/CN101932323A/zh active Pending
- 2008-10-29 MX MX2010003980A patent/MX2010003980A/es unknown
- 2008-10-29 RU RU2010116859/04A patent/RU2010116859A/ru not_active Application Discontinuation
- 2008-10-29 NZ NZ584846A patent/NZ584846A/en not_active IP Right Cessation
- 2008-10-29 EP EP08845782A patent/EP2207551A1/en not_active Withdrawn
- 2008-10-29 WO PCT/GB2008/051017 patent/WO2009056885A1/en active Application Filing
- 2008-10-29 AU AU2008320603A patent/AU2008320603A1/en not_active Abandoned
- 2008-10-29 JP JP2010531589A patent/JP2011502977A/ja active Pending
-
2010
- 2010-04-08 NI NI201000047A patent/NI201000047A/es unknown
- 2010-04-11 IL IL204990A patent/IL204990A0/en unknown
- 2010-04-29 EC EC2010010145A patent/ECSP10010145A/es unknown
- 2010-04-30 ZA ZA2010/03037A patent/ZA201003037B/en unknown
- 2010-04-30 CO CO10051730A patent/CO6321285A2/es not_active Application Discontinuation
- 2010-06-02 CR CR11473A patent/CR11473A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2009056885A1 (en) | 2009-05-07 |
AU2008320603A1 (en) | 2009-05-07 |
IL204990A0 (en) | 2010-11-30 |
CA2702134A1 (en) | 2009-05-07 |
ECSP10010145A (es) | 2010-08-31 |
US20110039877A1 (en) | 2011-02-17 |
ZA201003037B (en) | 2011-08-31 |
GB0721669D0 (en) | 2007-12-12 |
KR20100074234A (ko) | 2010-07-01 |
NZ584846A (en) | 2011-07-29 |
NI201000047A (es) | 2010-09-09 |
CN101932323A (zh) | 2010-12-29 |
RU2010116859A (ru) | 2011-12-10 |
EP2207551A1 (en) | 2010-07-21 |
MX2010003980A (es) | 2010-11-09 |
CR11473A (es) | 2010-11-11 |
JP2011502977A (ja) | 2011-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6321285A2 (es) | Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria | |
ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
ES2665917T3 (es) | Endoxifeno para su uso en el tratamiento del cáncer | |
CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
CR11100A (es) | Uso de inhibidores de piridopirimidinona de p13k-alfa en el tratamiento del cancer | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
CR11099A (es) | Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer | |
CL2008003284A1 (es) | Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
CL2008000795A1 (es) | Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto. | |
NI200800176A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión | |
HRP20090017T3 (en) | 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation | |
CR11483A (es) | Inhibidores de peptido desformilasa | |
CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
CL2009000914A1 (es) | Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica. | |
CR11859A (es) | Composición y proceso-356 | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. | |
CL2007002381A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis | |
AR056049A1 (es) | 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm | |
ECSP099506A (es) | Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |